- |||||||||| Review, Journal: Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review. (Pubmed Central) - Jul 11, 2024
These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta...However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Review, Journal: ALSUntangled #71: Nuedexta. (Pubmed Central) - Jul 26, 2023
Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA.
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
BLOOD CELL-SPECIFIC EXTRACELLULAR VESICLES FOR BLOOD-BASED STRATIFICATION OF DEMENTIA PATHOLOGY (On-Demand Oral Gallery C) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1082;
NeuroDex seems to identify the expected changes between diseases, and future studies will determine if co -morbidities can also be detected. We predict that dementia stratification based on pathology will boost therapeutic development.
- |||||||||| Auvelity (bupropion/dextromethorphan) / Axsome Therap
Journal: Dextromethorphan/bupropion (Auvelity) for depression. (Pubmed Central) - Dec 22, 2022
We predict that dementia stratification based on pathology will boost therapeutic development. No abstract available
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
BLOOD-BASED DEMENTIA PATHOLOGY STRATIFICATION UTILIZING NEURON-DERIVED EXOSOMES. () - Dec 9, 2022 - Abstract #CTAD2022CTAD_411;
The ability to detect different dementia-associated pathologies by a single blood test can be a game-changer for clinical trials and diagnosis. When fully developed, our blood test could provide a tool to screen the elderly population for better prognosis and treatment selection.
- |||||||||| Teglutik (riluzole oral suspension) / Italfarmaco, Exservan (riluzole oral soluble film) / Aquestive, Zambon, Mitsubishi Tanabe, Radicava (edaravone) / Mitsubishi Tanabe
Review, Journal: Biological aspects of nitrogen heterocycles for amyotrophic lateral sclerosis. (Pubmed Central) - Dec 9, 2022
• Neurodegenerative diseases and their drawbacks are discussed in detail. • Recent survey of nitrogen heterocycles in treating ALS disease are highlighted.
- |||||||||| Journal: Drugs for cognitive loss and dementia. (Pubmed Central) - Aug 28, 2022
• Recent survey of nitrogen heterocycles in treating ALS disease are highlighted. No abstract available
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Pseudobulbar Affect Mimicking Depression: A Case Report () - May 5, 2022 - Abstract #APA2022APA_606;
Although SSRI and TCA can be used for both depression and PBA, Nuedexta is the only FDA approved medication for PBA with clinical efficacy. Henceforth, the recognition and diagnosis of PBA is necessary to ensure appropriate treatment and improved quality of life.
- |||||||||| Review, Journal: Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. (Pubmed Central) - Jan 7, 2022
Furthermore, to date, most have demonstrated relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics. Of these novel agents, the most promising, and the ones for which the most evidence exists, appear to be those targeting ionotropic glutamate receptors.
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Trial completion: Impact of Nuedexta on Bulbar Physiology and Function in ALS (clinicaltrials.gov) - Nov 24, 2021
P1/2, N=28, Completed,
Such capacity can become transformative for the diagnosis and treatment development in the neurology space. Active, not recruiting --> Completed
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date: Impact of Nuedexta on Bulbar Physiology and Function in ALS (clinicaltrials.gov) - Nov 10, 2021
P1/2, N=28, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 28 | Trial completion date: Aug 2021 --> Dec 2021
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Trial completion date, Trial primary completion date: Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease (clinicaltrials.gov) - Apr 23, 2021
P3, N=22, Recruiting,
The authors hope that reporting this case will provide both context for physicians managing this condition and hope for patients with this socially and psychiatrically damaging disease. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| dextromethorphan deuterated/quinidine ultra-low dose (AVP-786) / Otsuka
Journal: AVP-786 as a promising treatment option for Alzheimer's Disease including agitation. (Pubmed Central) - Feb 23, 2021
Future phase III studies should use innovative study designs such as the Sequential Parallel Comparison Design to mitigate high placebo response, and the Cohen-Mansfield Agitation Inventory for agitation assessment. They should also include positron emission tomography studies to assess occupancy of various receptors in the brain after AVP-786 is administered.
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Trial completion date, Trial primary completion date: Impact of Nuedexta on Bulbar Physiology and Function in ALS (clinicaltrials.gov) - Jan 14, 2021
P1/2, N=40, Recruiting,
They should also include positron emission tomography studies to assess occupancy of various receptors in the brain after AVP-786 is administered. Trial completion date: Feb 2021 --> Aug 2021 | Trial primary completion date: Dec 2020 --> Aug 2021
- |||||||||| Neurodex (dextromethorphan hydrobromide/quinidine sulfate) / Otsuka
Functional Evaluation of the GluN2A-S644G Variant In Vitro and In Vivo, an NMDA Receptor Mutation Associated with Epileptic Encephalopathy (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_988;
Application of FDA-approved, NMDAR-specific drugs showed that Nuedexta (a combination of quinidine and dextromethorphan) to be the most effective at delaying the onset of lethal seizures in homozygous S644G mice...Given the role of NMDARs in neuronal development and synaptic plasticity, this mutation has likely altered circuit formation throughout the brain. Future studies will center around defining a critical window for therapeutic intervention and fully understanding how this genetic mutation rewires the brain to drive epileptic encephalopathy.
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Clinical protocol, Enrollment change, Trial termination: Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease (clinicaltrials.gov) - Nov 2, 2019
P4, N=34, Terminated,
Future studies will center around defining a critical window for therapeutic intervention and fully understanding how this genetic mutation rewires the brain to drive epileptic encephalopathy. N=60 --> 34 | Active, not recruiting --> Terminated; Sponsor decided to stop study early
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Enrollment open: Impact of Nuedexta on Bulbar Physiology and Function in ALS (clinicaltrials.gov) - Sep 11, 2019
P1/2, N=40, Recruiting,
N=60 --> 34 | Active, not recruiting --> Terminated; Sponsor decided to stop study early Not yet recruiting --> Recruiting
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Trial initiation date: Impact of Nuedexta on Bulbar Physiology and Function in ALS (clinicaltrials.gov) - Jun 12, 2019
P1/2, N=40, Not yet recruiting,
Not yet recruiting --> Recruiting Initiation date: May 2019 --> Aug 2019
- |||||||||| Journal: Glutamatergic Modulators in Depression. (Pubmed Central) - Jun 7, 2019
These results have prompted the repurposing or development of other glutamatergic modulators, both as monotherapy or adjunctive to other therapies. Here, we highlight the evidence supporting the antidepressant effects of various glutamatergic modulators, including (1) broad glutamatergic modulators (ketamine, esketamine, dextromethorphan, dextromethorphan-quinidine [Nuedexta], AVP-786, nitrous oxide [N2O], AZD6765), (2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (CP-101,606/traxoprodil, MK-0657 [CERC-301]), (3) glycine-site partial agonists (D-cycloserine, GLYX-13, sarcosine, AV-101), and (4) metabotropic glutamate receptor modulators (AZD2066, RO4917523/basimglurant, JNJ40411813/ADX71149, R04995819 [RG1578]).
- |||||||||| dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Enrollment open: Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease (clinicaltrials.gov) - Apr 19, 2019
P3, N=22, Recruiting,
Here, we highlight the evidence supporting the antidepressant effects of various glutamatergic modulators, including (1) broad glutamatergic modulators (ketamine, esketamine, dextromethorphan, dextromethorphan-quinidine [Nuedexta], AVP-786, nitrous oxide [N2O], AZD6765), (2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (CP-101,606/traxoprodil, MK-0657 [CERC-301]), (3) glycine-site partial agonists (D-cycloserine, GLYX-13, sarcosine, AV-101), and (4) metabotropic glutamate receptor modulators (AZD2066, RO4917523/basimglurant, JNJ40411813/ADX71149, R04995819 [RG1578]). Not yet recruiting --> Recruiting
|
